These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19372835)

  • 1. Recent advances of CCR5 antagonists.
    Baba M
    Curr Opin HIV AIDS; 2006 Sep; 1(5):367-72. PubMed ID: 19372835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.
    Latinovic O; Heredia A; Gallo RC; Reitz M; Le N; Redfield RR
    Antiviral Res; 2009 Jul; 83(1):86-9. PubMed ID: 19501260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
    Emmelkamp JM; Rockstroh JK
    Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N; Solomon K; Zhou N; Wang KH; Garlapati V; Thomas B; Li Y; Covington M; Baribaud F; Erickson-Viitanen S; Czerniak P; Contel N; Liu P; Burn T; Hollis G; Yeleswaram S; Vaddi K; Xue CB; Metcalf B; Friedman S; Scherle P; Newton R
    J Pharmacol Exp Ther; 2011 Jul; 338(1):228-39. PubMed ID: 21459966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay.
    Labrecque J; Metz M; Lau G; Darkes MC; Wong RS; Bogucki D; Carpenter B; Chen G; Li T; Nan S; Schols D; Bridger GJ; Fricker SP; Skerlj RT
    Virology; 2011 May; 413(2):231-43. PubMed ID: 21388649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CCR5 antagonists: a new class of antiretrovirals].
    Peytavin G; Calvez V; Katlama C
    Therapie; 2009; 64(1):9-16. PubMed ID: 19463248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR5 antagonists for the treatment of HIV.
    Barber CG
    Curr Opin Investig Drugs; 2004 Aug; 5(8):851-61. PubMed ID: 15600241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.
    Strizki JM; Tremblay C; Xu S; Wojcik L; Wagner N; Gonsiorek W; Hipkin RW; Chou CC; Pugliese-Sivo C; Xiao Y; Tagat JR; Cox K; Priestley T; Sorota S; Huang W; Hirsch M; Reyes GR; Baroudy BM
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4911-9. PubMed ID: 16304152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV entry: new insights and implications for patient management.
    Hughes A; Nelson M
    Curr Opin Infect Dis; 2009 Feb; 22(1):35-42. PubMed ID: 19532079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to CCR5 antagonists.
    Westby M
    Curr Opin HIV AIDS; 2007 Mar; 2(2):137-44. PubMed ID: 19372879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
    Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S
    J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
    Seto M; Aikawa K; Miyamoto N; Aramaki Y; Kanzaki N; Takashima K; Kuze Y; Iizawa Y; Baba M; Shiraishi M
    J Med Chem; 2006 Mar; 49(6):2037-48. PubMed ID: 16539392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.
    Demarest JF; Sparks SS; Schell K; Shibayama S; McDanal CB; Fang L; Adkison KK; Shachoy-Clark A; Piscitelli SC
    J Clin Pharmacol; 2008 Oct; 48(10):1179-88. PubMed ID: 18676693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.
    Westby M; van der Ryst E
    Antivir Chem Chemother; 2005; 16(6):339-54. PubMed ID: 16329283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV.
    Kiser JJ
    Curr Opin HIV AIDS; 2008 May; 3(3):330-41. PubMed ID: 19372987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent.
    Ma D; Yu S; Li B; Chen L; Chen R; Yu K; Zhang L; Chen Z; Zhong D; Gong Z; Wang R; Jiang H; Pei G
    ChemMedChem; 2007 Feb; 2(2):187-93. PubMed ID: 17163560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.
    Ji C; Brandt M; Dioszegi M; Jekle A; Schwoerer S; Challand S; Zhang J; Chen Y; Zautke L; Achhammer G; Baehner M; Kroetz S; Heilek-Snyder G; Schumacher R; Cammack N; Sankuratri S
    Antiviral Res; 2007 May; 74(2):125-37. PubMed ID: 17166600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.